Prostate News Archive
16-Feb-2009
Bone Turnover Markers As Predictive Tools For Skeletal Complications In Men With Metastatic Prostate Cancer Treated ... (Medical News Today)
UroToday.com - Bisphosphonates such as zoledronic acid (ZA) are used to prevent skeletal complications from prostate cancer (CaP) metastatic to bone. Bone scintigraphy is used to diagnose bone metastasis and to monitor response to therapy. Bone turnover markers measured in serum and urine are proposed to predict which patients with bone metastasis are at risk of skeletal complications. Discovery of metabolite linked to aggressive prostate cancer (News-Medical-Net)
Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer. Better prostate cancer treatment hope (The Telegraph)
New Delhi, Feb. 15: Scientists have spotted a new chemical fingerprint of aggressive prostate cancer that may lead to better diagnosis and effective treatment strategies tailored for individual patients. Randomized Controlled Trial Of Resistance Or Aerobic Exercise In Men Receiving Radiation Therapy For Prostate Cancer (Medical News Today)
UroToday.com - Fatigue is the most common complaint among patients undergoing radiotherapy (XRT) for prostate cancer (CaP) and occurs in 60-80% of these men. It persists after treatment is completed and can decrease quality-of-life and functional capacity. In the December 2008 issue of the Journal of Clinical Oncology, Dr.
Back to Prostate News Archive
